Truist Securities Reiterates Buy Rating on Nurix Therapeutics

Truist Securities reiterated its buy rating on Nurix Therapeutics, Inc. (NasdaqGM: NRIX) on June 9, 2026. Analyst Gregory Renza set a price target of $32 for the stock, which recently traded at $17.96.

Analysts Set New Price Targets

On June 9, 2026, Truist Securities maintained its buy rating on Nurix Therapeutics, setting a $32 price target. BTIG also maintained its buy rating with the same target on the same day. Earlier, on June 8, Jefferies set a higher target of $45, while Wells Fargo maintained a $25 target. Needham also maintained its buy rating with a $34 target.

Other Institutional Activity in Nurix Therapeutics

BlackRock, Inc. increased its holdings in Nurix Therapeutics by 50,448 shares, resulting in a total of 8,925,642 shares worth about $138.3 million. Redmile Group, LLC reduced its position by 361,100 shares, now holding 7,732,808 shares valued at approximately $119.9 million. Vestal Point Capital, LP significantly boosted its stake by 1,810,000 shares to 6,500,000 shares, valued around $100.8 million. Deep Track Capital, LP cut its holdings by 691,211 shares, leaving it with 6,345,244 shares worth about $98.4 million. FMR LLC added 1,307,113 shares, now holding 5,541,271 shares valued at $85.9 million.

Nurix Therapeutics, Inc. Stock Down 35.3%

Shares of Nurix Therapeutics, Inc. (NasdaqGM: NRIX) recently traded near $17.96. The company has a market cap of approximately $1.75 billion and a beta of 1.87. Its 52-week range is $8.20 to $22.50, with a 50-day moving average of $16.43 and a 200-day moving average of $14.92. Nurix has a current ratio of 6.01 and a quick ratio of 5.89.

Recent Earnings

Nurix Therapeutics reported revenue of $71.78 million, though it experienced a revenue decline of 66.1%. The company posted a net margin of 0.0% and a return on equity of -61.4%. The next earnings report is expected on April 8, 2026.

Insider Buying and Selling at Nurix Therapeutics, Inc.

On June 2, 2026, Christine Ring, Chief Legal Officer, executed a planned sale of 8,148 shares at an average price of $16.60. Previously, on May 15, 2026, insiders Roy Baynes, Paul Silva, and Edward Saltzman each purchased 31,250 shares.

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a biotechnology company based in Brisbane, California. It focuses on developing therapies for cancer, inflammatory conditions, and other diseases. The company is led by CEO Dr. Arthur T. Sands and employs 317 people. Nurix is known for its small molecule and antibody therapies and has strategic collaborations with major companies like Gilead Sciences, Sanofi, and Pfizer.

Bottom Line

Truist Securities' reiterated buy rating and $32 price target reflect continued confidence in Nurix Therapeutics' potential. Investors monitor these updates as part of their due diligence, but it's important to remember that analyst ratings are just one factor in assessing a stock's prospects.